More News! 24 Jun 2022 Gurnet Point Capital and Patient Square Capital buy Radius Health for $890M Global pharmaceutical company, Radius Health Inc, announced this week (June 23) that it has entered into a definitive agreement to be bought out by Gurnet Point Capital and Patient Square Capital in a transaction valued at approximately $890 million. Radius Health is a company focused on addressing unmet medical needs in the areas of bone […] June 24, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jun 2022 Stramsen Biotech to look at 11 plant-based drug candidates Houston-based biotechnology firm Stramsen Biotech Inc. has announced 11 drug candidates for clinical development. Kefas Mugittu, co-CEO, made the announcement of the plant-based medical candidates. The company said the drugs are safe, effective and currently in use in different countries. The drug candidates are: SBX 1052, which controls/prevents enlargement of the prostate glands; SBX1968, which […] June 24, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jun 2022 Study reveals progress for those with hepatitis B A clinical-stage biopharma company has announced its study of product VTP-300 for use in patients with hepatitis B has resulted in positive safety and efficacy data. Vaccitech plc deals with novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmune diseases. The updated analysis includes 39 patients with at least […] June 24, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jun 2022 Covid and malaria vaccines on track for mass production in Rwanda Construction of the first African messenger RNA (mRNA) manufacturing facility has started in Africa. This means Biopharmaceutical New Technologies (BioNTech) SE is a step closer to producing mRNA vaccines that teach human cells how to make a protein that will trigger an immune response inside the body. The company is a next generation immunotherapy company […] June 24, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jun 2022 Second dairy cellular agtech incubator program Mylkcubator opens Pascual, a Spanish manufacturer of dairy products and beverages, has launched Mylkcubator 2.0, the second edition of its global incubation program for cellular agriculture technologies in the dairy industry. The initiative has been launched from the group’s Corporate Venture unit, Pascual Innoventures, in collaboration with Eatable Adventures, a global foodtech accelerator. Mylkcubator 2.0 will last […] June 24, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jun 2022Beyond Biotech podcast 2: Asabys, Asebio, MOA Foodtech This week’s podcast is dedicated to Spain. We have conversations with bioindustry association AseBio’s CEO, Ion Arocena; Clara Campàs, managing partner and co-founder of venture capital company Asabys, and Susana Sánchez Gómez, co-founder and chief scientific officer at MOA Foodtech. AseBio, the Spanish Bioindustry Association, brings together and represents the interests of companies, associations, foundations, […] June 24, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2022 Evaxion Biotech picks candidate for lung cancer trial A clinical-stage biotech company that specializes in developing AI-driven immunotherapies has chosen its product candidate for an upcoming clinical trial for patients with advanced lung cancer. Evaxion Biotech selected EVX-03 within its DNA technology platform to target a new indication based on what it said are very encouraging results from pre-clinical studies. EVX-03 is optimized […] June 23, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2022 Antheia gets funding to build biomanufacturing plant Antheia, a U.S. synthetic biology company enabling next-generation plant-inspired medicines, has announced $40 million in venture debt financing from Oxford Finance LLC and Silicon Valley Bank. The company also unveiled plans to construct a new pilot scale biomanufacturing facility. The financing will support Antheia’s expansion with a 14,700 square-foot pilot plant located next to Antheia’s […] June 23, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2022 Osivax gets €10M influenza vaccine grant A grant of €10 million ($10.5 million) has been secured by pharmaceutical company Osivax to support a vaccine against influenza. The biopharma company develops vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases. It announced today (June 23) that it has secured the funds from Bpifrance to support the further clinical development […] June 23, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2022 Scancell to produce and clinically validate T cell redirecting bispecific antibodies Scancell Holdings plc, which develops immunotherapies for the treatment of cancer and infectious disease, has announced it will develop its GlyMab antibodies into T cell redirecting bispecific (TCB) antibodies and take them into the clinic. The UK company said this is a promising new therapeutic approach to treat cancer. TCB antibodies have dual-binding specificity, which […] June 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2022 Krystal Biotech looks for FDA approval for dystrophic epidermolysis bullosa treatment U.S. gene therapy company Krystal Biotech, Inc, has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of B-VEC (beremagene geperpavec) for the treatment of patients with dystrophic epidermolysis bullosa (DEB). B-VEC is an investigational non-invasive, topical gene therapy designed to treat DEB at the molecular level by […] June 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 23 Jun 2022 The biggest Asia-Pacific biotech investments in May 2022 Healthcare-focused biotech companies won the biggest private investments in the Asia-Pacific region in May 2022, led by a $100 million Series A from the Chinese anti-inflammatory drug developer Reistone Biopharma. In the Asia-Pacific region, Chinese biotechs generally took home the biggest private funding rounds in May 2022. The top rank went to Reistone Biopharma, located […] June 23, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email